Organon to Acquire Dermavant and VTAMA Cream in $175 Million APA Deal

Sep 18, 2024, 11:35 AM

Organon has announced its acquisition of Dermavant, including its innovative dermatologic therapy, VTAMA (tapinarof) Cream 1%. The deal includes an upfront payment of $175 million, with additional payments up to $1.2 billion based on sales milestones. An additional $75 million is contingent on VTAMA's approval in AtD. This acquisition, structured as an APA, highlights Organon's commitment to expanding its dermatology portfolio.